Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 10/20 | 0.34 |
| ▸ | MAOA | P21397 | 8/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.32 |
| ▸ | CDC25B | P30305 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | HPD | P32754 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.30 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7714704 | 1.00 | LMNA (0.38) | LMNAMAOBMAOAIDO1PTPN1 | |
| SCHEMBL1028137 | 0.86 | LMNA (0.52) | LMNAPTPN1CDC25B | |
| SCHEMBL7019706 | 0.86 | LMNA (0.52) | LMNAPTPN1CDC25B | |
| SCHEMBL2412297 | 0.74 | IDO1 (0.44) | LMNAMAOBIDO1ALDH1A1HPGD | |
| SCHEMBL2412299 | 0.74 | IDO1 (0.44) | LMNAMAOBIDO1ALDH1A1HPGD | |
| SCHEMBL13544337 | 0.70 | SMN1; SMN2 (0.49) | LMNAPTPN1CDC25BALDH1A1SMN1; SMN2 | |
| SCHEMBL6961092 | 0.68 | TDP1 (0.53) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL4598273 | 0.67 | IDO1 (0.47) | IDO1 | |
| SCHEMBL18077555 | 0.66 | CYP2C9 (0.38) | LMNAMAOBALDH1A1 | |
| SCHEMBL14635989 | 0.65 | GRM2 (0.43) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6369223-B2 | USING CATALYST COMPLEX | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-04-09 | — | — | US | disclosed |
| US-20020004602-A1 | Asymmetric cycloaddition reactions | JACOBSEN ERIC N (US) | 2002-01-10 | — | — | US | disclosed |
| US-6211370-B1 | REACTING A DIENOPHILE WITH A 1,3-DIENE | HARVARD UNIVERSITY | 2001-04-03 | — | — | US | disclosed |
| US-6130340-A | CATALYST SELECTIVITY; DRUG CHEMICAL INTERMEDIATES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2000-10-10 | — | — | US | disclosed |
| WO-1999036375-A1 | ASYMMETRIC CYCLOADDITION REACTIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1999-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004602-A1 | Asymmetric cycloaddition reactions | PAPSS1, SPR, CMKLR1 | LMNA 4816/4885MAOB 2134/4885MAOA 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.